The TGF-R1 inhibitor galunisertib re-shapes the PDAC-TME by limiting decidual-like natural killer cells polarization
Research article published in Cell death & disease (2026)
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related mortality worldwide. Natural Killer (NKs) cells are pivotal for tumor surveillance but are dysfunctional in PDAC. We evaluated whether pharmacological blockade of TGF-β1/TGF-βR1 axis in PDAC cells and cancer-associated fibroblasts (CAFs) could modulate NK polarization via soluble factors. The phenotype/functions of NKs from PDAC patients versus healthy controls (HC) were compared, and the polarization state of NKs exposed to the conditioned media of PDAC cells and fibroblasts was evaluated by flow cytometry. The ability of galunisertib (GAL) to reverse NK dysfunction in immunocompetent mice orthotopically implanted with FC1199 PDAC cells was evaluated. PDAC patients showed higher TGF-β1/ TGF-βR1 levels than HC, with worse outcomes in TGF-β1high/TGF-βR1high patients. Circulating CD9+ NKs were expanded in PDAC patients compared with HC and exhibited a pro-angiogenic secretome and higher pro-angiogenic activities in vitro and in vivo (leech Hirudo verbana), compared to the CD9- NK cells. PDAC cells and CAF induced a CD9+-decidual-like phenotype, also impairing NK degranulation. GAL treatment restrains PDAC cell/CAF-induced NK anergy, restoring their cytotoxicity. Also, TGFβ-R1 knockdown in PDAC cells exhibited the capability to limit the generation of decidual-like NKs, while restoring their antitumor ability, via soluble factors. Secretome profiling of BxPC3 and MIAPaCA2 PDAC cell lines and CAFs showed that GAL downregulated the release of several growth, angiogenic, and immunoregulatory factors, including FGF2, HGF, IL11, PLGF, EGFR, and VEGF. In vivo in orthotopic tumors formed by FC1199 cells GAL decreased CD9+-NK frequency, promoted M1-macrophage polarization, and activated NK and CD8+T-cells, together with a significant reduction of tumor weight, fibrosis and inhibition of angiogenesis. Our study identifies CD9+NKs as a novel cell subset expanded in PDAC and underscores the role of TGF-β1/TGF-βR1 signalling in promoting a pro-tumoral NKs GAL-treatment emerges as immunomodulator able in re-educating pro-tumor NKs cells in PDAC.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related mortality worldwide.
Warum dies für die Hirudotherapie relevant ist
This study examined TGF-β1/TGF-βR1 blockade by galunisertib in pancreatic ductal adenocarcinoma, focusing on decidual-like CD9+ NK cell polarization and tumor microenvironment remodeling. Among the methods, the angiogenic activity of CD9+ vs. CD9- NK cells was compared using an in vivo angiogenesis assay in the leech Hirudo verbana. The study found that CD9+ NKs exhibited pro-angiogenic activity and that galunisertib restored NK cytotoxicity and reduced tumor growth and angiogenesis in orthotopic mice. For ASH's domain, Hirudo verbana appears as an in vivo angiogenesis bioassay model, which is tangentially relevant because it demonstrates a scientific use of a medicinal leech species. However, the study is not about hirudotherapy; the leech is used solely as a surrogate assay organism for measuring angiogenic responses, making the connection to clinical leech therapy or the leech secretome indirect and limited.
Zitation
The TGF-R1 inhibitor galunisertib re-shapes the PDAC-TME by limiting decidual-like natural killer cells polarization
Cucchiara M et al. · Cell death & disease, 2026
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026